Medical Research

Moderate evidence that cannabis-based medicines may be effective for chronic pain. Patients reported a 30% reduction in pain scores compared to placebo across multiple RCTs.

Cannabis can be effective treatment for chronic pain in adults. Preclinical and clinical data support analgesic properties through multiple mechanisms.

Vaporized cannabis produced dose-dependent reductions in diabetic peripheral neuropathy pain. Low-dose cannabis (1.29% THC) was as effective as medium dose (3.53%).

Cannabis-based medicines may increase the number of people achieving 50% or greater pain relief compared with placebo. NNT of 11 for substantial benefit.

After 6 months of medical cannabis treatment, 81.1% of fibromyalgia patients reported moderate or significant improvement. 73.4% reduced or stopped other medications.

US states with medical cannabis laws had 14.4% lower rate of opioid prescriptions and 6.38% lower rate of opioid overdose deaths.

CBD reduced convulsive-seizure frequency from a median of 12.4/month to 5.9/month (vs 14.9 to 14.1 with placebo). Led directly to FDA approval of Epidiolex.

CBD significantly reduced the frequency of drop seizures by 41.9% (vs 17.2% placebo). Confirmed CBD's anti-seizure properties across multiple seizure types.

CBD maintained effectiveness over 2+ years of treatment with 50% of patients experiencing at least 50% reduction in seizures. Safety profile remained consistent.

Strong preclinical evidence supports CBD as a treatment for generalized anxiety disorder, panic disorder, social anxiety, OCD, and PTSD with a notable absence of anxiogenic effects.

Pretreatment with CBD significantly reduced anxiety, cognitive impairment, and discomfort during public speaking simulation. Effects were comparable to ipsapirone.

91% of PTSD patients treated with CBD showed decrease in symptom severity. Mean PCL-5 score decreased from 51.82 to 37.14 over 8 weeks.

CBD anxiolytic effects demonstrated consistently. THC shows biphasic response: low doses anxiolytic, high doses anxiogenic. Dose and ratio matter significantly.

THC:CBD combination significantly reduced cancer-related pain in patients refractory to opioid therapy. 43% achieved clinically meaningful pain reduction.

CBD and THC reduced tumor growth and metastasis in preclinical HER2+ breast cancer models. Cannabinoids inhibited cancer cell proliferation and induced apoptosis.

Delta-8-THC completely prevented vomiting in pediatric cancer patients undergoing chemotherapy with a 100% success rate across 480 treatments. Very few side effects.

THC:CBD oromucosal spray (Sativex) significantly reduced MS-related spasticity. Now approved in 30+ countries for this indication.

CBD showed neuroprotective properties, reducing neuroinflammation and oxidative stress in preclinical models. May slow disease progression through multiple mechanisms.

CBD improved quality of life and well-being measures in Parkinson's patients. Sleep quality improved significantly. Motor symptoms showed modest improvement.

CBD reduced intestinal inflammation markers by 50% in preclinical models. Human trials show promising preliminary results for Crohn's and ulcerative colitis.

CB2 receptor activation by cannabinoids reduces proinflammatory cytokines and immune cell migration. CBD, CBG, and beta-caryophyllene show strongest anti-inflammatory profiles.

Daily use of high-potency cannabis (>10% THC) associated with increased risk of psychotic disorders. Risk was dose-dependent. Important safety data.

THC decreases sleep onset latency but may impair long-term sleep quality. CBD may hold promise for REM sleep behavior disorder and excessive daytime sleepiness.

15mg THC appeared sedating while 15mg CBD appeared to have alerting properties. THC reduced REM sleep latency and increased slow-wave sleep.

CBD significantly reduced both craving and anxiety induced by drug cues in heroin-abstinent individuals. Effects persisted for 7 days after treatment.

Preliminary evidence supports CBD for cannabis, tobacco, and opioid use disorders. CBD may reduce drug-seeking behavior through modulation of the dopaminergic system.

Topical cannabinoids show promise for eczema, psoriasis, pruritus, and wound healing. CBD's anti-inflammatory properties effective for acne through sebum regulation.

Cannabis use associated with increased heart rate acutely. Long-term cardiovascular risks remain unclear. CBD may have cardioprotective properties through anti-inflammatory mechanisms.

Evidence strongest for PTSD and social anxiety. Mixed results for depression. CBD shows anxiolytic effects across multiple models. THC biphasic response confirmed.

After CBD-enriched cannabis treatment, 80% of ASD patients reported improvement in behavioral problems. Self-injury and rage attacks significantly decreased.

Cannabinoids modulate immune responses by suppressing pro-inflammatory Th1/Th17 cells and enhancing anti-inflammatory Treg cells. Implications for autoimmune diseases.